LAG3 and neoplasm: Targeting tumor-specific T cells, therapeutic interceptions that inhibit receptors, including PD1 (pembrolizumab, nivolumab), CTLA4 (ipilimumab, tremelimumab) and LAG3 (BMS-986,016), have been approved or are in clinical trials for the treatment of various cancer types [124].